Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.

Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.

Abstract: Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).

Abstract: Provided are a composition and the uses thereof. Said composition comprises Megamonas funimormis and/or a metabolite thereof, as well as Anaerofustis stercorihominis and/or a metabolite thereof. Said composition can efficiently treat and prevent inflammation, specifically ulcerative colitis, and related diseases thereof by using a combination of Megamonas funimormis and Anaerofustis stercorihominis, and is safe, efficient, exhibits low toxicity and does not easily produce resistance.

Abstract: The invention provides a catheter positioning device which comprises a base fixed on a body, a positioning guide groove arranged on the base, and a self-locking module positioned on two opposite sides or one side of the positioning guide groove, wherein when the catheter is positioned at a preset position in the positioning guide groove, the self-locking module is in a released state; and when the catheter moves relative to the positioning guide groove to deviate from the preset position, the self-locking module is triggered to switch from the released state to a locking state, so that the self-locking module in locking state limits the movement of the catheter relative to the positioning guide groove so as to achieve the technical effect of positioning the catheter.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Provided is a use of Butyribacter intestini in preventing and/or treating inflammation-related diseases. Specifically, in the present disclosure, it was firstly discovered that Butyribacter intestini has the function of preventing and/or treating inflammation-related diseases (for example, inflammatory bowel disease, such as ulcerative colitis, gastritis, and common enteritis; and rheumatoid arthritis).

Abstract: A semiconductor device and a fabricating method thereof are provided. The semiconductor device includes a semiconductor structure and an input/output pad. The semiconductor structure includes a first substrate and a conductive layer, in which the first substrate has a first surface and a second surface opposite to each other, the conductive layer is disposed on the first surface of the first substrate, and the conductive layer includes one or more first trace. The first semiconductor structure has a recess penetrating the first substrate and exposing the one or more first trace, and the input/output pad is disposed on the one or more first trace and in the recess.

Abstract: Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.

Abstract: Provided are Megamonas funiformis and applications thereof. Specifically, the Megamonas funiformis has the effects for preventing and/or treating inflammation-related diseases, such as inflammatory bowel diseases (such as ulcerative enteritis, gastritis, and general enteritis) and cardiovascular diseases.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.

Abstract: Provided are Christensenella intestinihominis and an application thereof, specifically, use of Christensenella intestinihominis in treating and preventing obesity and related diseases thereof. Also provided are a composition for treating and preventing obesity and related diseases thereof, comprising compositions of drugs, drinks, food, or animal feed, and a method for reducing weight and/or blood lipid.

Abstract: Provided are Faecalibacterium longum and an application thereof, specifically, use of Faecalibacterium longum in treating and preventing diabetes and related diseases thereof. Also provided are a composition for treating and preventing diabetes and related diseases thereof, comprising compositions of drugs, drinks, food, or animal feed, and a method for reducing weight, fasting plasma glucose and/or blood lipid, and improving glucose tolerance.

Abstract: The present disclosure relates to a light guide plate and its fabricating method, as well as a backlight module. The light guide plate comprises a light-transmitting plate body provided with a plurality of light guide dots on a light-exiting surface thereof, and further provided with a plurality of dimming pits, wherein a plurality of light guide dots are provided around each of the dimming pits; an inner wall of each of the dimming pits sequentially includes multiple levels of dimming surfaces along a depth direction of the dimming pits, for reflecting light incident thereon to the light guide dots. The backlight module comprises the light guide plate provided in the above-described technical solution.

Abstract: A display device is provided. The display device includes a display screen and an optical film structure arranged on a light exiting side of the display screen. The optical film structure includes a substrate layer and a first micro-lens array layer, where the substrate layer has a first surface and a second surface opposite to each other; the first micro-lens array layer is provided on at least one of the first surface and the second surface, and includes multiple micro-lenses arranged in sequence, each of the multiple micro-lenses has a size smaller than that of a sub-pixel, and edges of adjacent micro-lenses abut on each other.

Abstract: Embodiments of this application relate to the field of terminal technologies, and describe a method for displaying a dynamic image and a terminal, which resolve a problem that power consumption of a terminal caused by an existing method in which three-dimensional real-time rendering is used is relatively high. The method may be applied to a terminal, and can includes obtaining, from a video file based on a preset factor, a plurality of pieces of image frame data in a one-to-one correspondence to a plurality of image frames. The method may also include decoding the plurality of pieces of image frame data, to obtain the plurality of image frames. Furthermore, the method can include successively displaying the plurality of image frames obtained through the decoding, to present the dynamic image. The dynamic image includes the plurality of image frames, and the preset factor includes at least one of the following factors: a time point and orientation data.

Abstract: The present invention discloses an application of Bacteroides cellulosilyticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases, such as atherosclerosis related diseases, cardiovascular diseases and obesity.